Carcinogenesis, Vol. 20, No. 6, 991-995,
June 1999
© 1999 Oxford University Press
Molecular Epidemiology and Cancer Prevention |
Analyses of bronchial bulky DNA adduct levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseases
1 Division of Molecular Epidemiology (HFT-100), National Center for Toxicological Research, Jefferson, AR 72079, USA,
2 Department of Biochemistry, National Institute of Environmental Health, H-1097 Budapest, Hungary and
3 Thoracic Surgical Clinic, Korányi National Institute of Pulmonology, Budapest, H-1529 Hungary
4 Present address: Department of Pharmacology, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158, Japan
Carcinogen–DNA adducts may represent an intermediate end-point in the carcinogenic cascade and may reflect exposure to chemical carcinogens, as well as susceptibility and, ultimately, cancer risk. Interindividual variability in activity of enzymes involved in the metabolism of polycyclic aromatic hydrocarbons to mutagenic diol epoxides may predict adduct levels and, indirectly, lung cancer risk. Using 32P-postlabeling methods, the levels of bulky DNA adducts were determined in macroscopically normal bronchial tissues obtained from resected lobes of 143 Hungarian patients with lung malignancy and other pulmonary conditions. DNA from normal tissue was also evaluated for polymorphisms in cytochrome P450 2C9 (CYP2C9) at two sites, codons 144 (Arg/Cys) and 359 (Ile/Leu), for glutathione S-transferase P1 (GSTP1) at codon 105 and for NAD(P)H:quinone oxidoreductase (NQO1) at codon 187 (Pro/Ser). Using the Mann–Whitney U-test and analysis of variance, levels of adducts were evaluated in relation to variant genotypes, separately for smokers and non-smokers. As previously reported, bulky DNA adduct levels in smokers (n = 104) were estimated to be 54% higher than in non-smokers (n = 39) (8.6 ± 4.2 versus 5.6 ± 3.3 per 108 nucleotides, respectively, P < 0.01). Adduct levels were 16–29% higher in individuals with the homozygous Ile359/Ile359 CYP2C9 allele than in those heterozygous for the variant allele (Ile359/Leu359) [8.8 ± 4.3 (n = 84) versus 7.6 ± 3.5 (n = 20) for smokers and 5.8 ± 3.5 (n = 32) versus 4.5 ± 1.3 (n = 7) for non-smokers], although differences were not statistically significant. There were no clear differences in adduct levels in relation to genotypes of NQO1 or GSTP1. Although numbers of patients in this study are large in relation to many studies of carcinogen–DNA adducts, it is still possible that significant differences were not noted for polymorphisms in xenobiotic metabolizing enzymes due to relatively small numbers in stratified data.
Abbreviations: anti-BPDE, anti-benzo[a]pyrene 7,8-diol 9,10-epoxide; B[a]P, benzo[a]pyrene; CYP, cytochrome P450; GST, glutathione S-transferase; NQO1, NAD(P)H:quinone oxidoreductase; PAH, polycyclic aromatic hydrocarbon.
5 To whom correspondence should be addressed Email: fkadlubar{at}nctr.fda.gov
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Alexandrov, I. Cascorbi, M. Rojas, G. Bouvier, E. Kriek, and H. Bartsch CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation Carcinogenesis, December 1, 2002; 23(12): 1969 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Jacobs and D. C. Zeldin The lung HETEs (and EETs) up Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H1 - H10. [Abstract] [Full Text] [PDF]
|
|